Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Yanru Qiao, MS
Research Assistant
Department of Clinical Pharmacy
University of Tennessee College of Pharmacy
Memphis, TN
Research Assistant, Department of Clinical Pharmacy, University of Tennessee College of Pharmacy, Memphis
Authored Items
Effects of Medicare Part D on Disparity Implications of Medication Therapy Management Eligibility Criteria
Marie Chisholm-Burns, PharmD, MPH, MBA, FCCP, FASHP
,
William C. Cushman, MD
,
Samuel Dagogo-Jack, MD, FRCP
,
JoEllen Jarrett Jamison, BS
,
Liyuan Li, PhD
,
Yanru Qiao, MS
,
Ya-Chen Tina Shih, PhD
,
Christina A. Spivey, PhD
,
Jim Y. Wan, PhD
,
Junling Wang, PhD
,
Shelley I. White-Means, PhD
,
Dima M. Qato, PharmD, MPH, PhD
September 2014 Vol 7, No 6
in
Practice Management
Last modified: October 1, 2014